BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36569901)

  • 21. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
    Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
    Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
    Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
    J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunocytokines with target cell-restricted IL-15 activity for treatment of B cell malignancies.
    Zekri L; Hagelstein I; Märklin M; Klimovich B; Christie M; Lindner C; Kämereit S; Prakash N; Müller S; Stotz S; Maurer A; Greve C; Schmied B; Atar D; Rammensee HG; Jung G; Salih HR
    Sci Transl Med; 2024 Mar; 16(737):eadh1988. PubMed ID: 38446900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
    Beum PV; Lindorfer MA; Taylor RP
    J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
    Funakoshi S; Longo DL; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
    Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.
    Evers M; Ten Broeke T; Jansen JHM; Nederend M; Hamdan F; Reiding KR; Meyer S; Moerer P; Brinkman I; Rösner T; Lebbink RJ; Valerius T; Leusen JHW
    MAbs; 2020; 12(1):1795505. PubMed ID: 32744145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
    Waldhauer I; Gonzalez-Nicolini V; Freimoser-Grundschober A; Nayak TK; Fahrni L; Hosse RJ; Gerrits D; Geven EJW; Sam J; Lang S; Bommer E; Steinhart V; Husar E; Colombetti S; Van Puijenbroek E; Neubauer M; Cline JM; Garg PK; Dugan G; Cavallo F; Acuna G; Charo J; Teichgräber V; Evers S; Boerman OC; Bacac M; Moessner E; Umaña P; Klein C
    MAbs; 2021; 13(1):1913791. PubMed ID: 33974508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
    Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
    Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
    Winiarska M; Bil J; Wilczek E; Wilczynski GM; Lekka M; Engelberts PJ; Mackus WJ; Gorska E; Bojarski L; Stoklosa T; Nowis D; Kurzaj Z; Makowski M; Glodkowska E; Issat T; Mrowka P; Lasek W; Dabrowska-Iwanicka A; Basak GW; Wasik M; Warzocha K; Sinski M; Gaciong Z; Jakobisiak M; Parren PW; Golab J
    PLoS Med; 2008 Mar; 5(3):e64. PubMed ID: 18366248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis.
    Chen Y; Chen L; Lu Q; Meng Y; Wang C; Wang L; Wang H; Yu X; Zhang Y; Zhao L; Li B; Guo Y
    Biochem Biophys Res Commun; 2015 Apr; 459(4):617-22. PubMed ID: 25749344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.